12:00 AM
 | 
Mar 08, 1999
 |  BC Week In Review  |  Company News  |  Deals

Neurocrine, Wyeth-Ayerst deal

The companies will develop compounds that modulate excitatory amino acid transporters (EAATs) to treat neurodegenerative and psychiatric diseases. NBIX...

Read the full 73 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >